The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients

Albaker, Waleed; Sheikh, M; Albakr, Aishah; Alkhafaji, Dania; Besher, Eman Al; Al-Hariri, Mohammed

doi:10.2147/ijgm.s336904

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…was a non-significant reduction in SBP and a slight significant increase in DBP by 2.4 mmHg in the entire cohort at 6 months of treatment with Liraglutide 3.0 mg. Our findings follow previous studies reporting a slight increase in DBP by 2 mmHg in a retrospective cohort study in Saudi outpatients 33 and a non-significant increase in DBP in patients studied in Canada. 23 However, we found a non-significant decrease in the TC and ALT levels with 2, 4 and 6 months of Liraglutide 3.0 mg treatments in the selected PwO.…”

Section: Discussionsupporting

confidence: 92%

Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity‐related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real‐world experience

Alshehri,

AlFaris,

Al Qahtani

et al. 2023

Clinical Obesity

View full text Add to dashboard Cite

Obesity has emerged as one of the most challenging worldwide problems and, if left untreated, can lead to major illnesses and consequences that can impair patients' health The study's objective was to evaluate the effectiveness of Liraglutide 3.0 mg in inducing weight loss and to assess the improvement of obesity-related comorbid conditions among people living with obesity (PwO) in the Kingdom of Saudi Arabia (KSA). A retrospective cohort review of PwO with or without diabetes and taking Liraglutide 3.0 mg in combination with diet and exercise for weight management was performed and evaluated at King Fahad Medical City, Riyadh, KSA. We collected patient data from electronic medical records for different parameters. The side effects were not recorded. A cohort of 399 patients who used Liraglutide 3.0 mg for 6 months was included in the study. At baseline, the mean age of the cohort was 46.4 (±12.1) years, mean BMI was 40.4 (±7.7) kg/m 2 and most patients (74.4%) were women. Their mean average weight loss was 6.5 (±9.5) kg; p < .001. In the entire cohort, 52.6% of subjects had lost ≥5% of their bodyweight, 27.8% of subjects had lost ≥10%, and 11.3% of subjects had lost ≥15% of their bodyweight. There was a significant reduction in HbA1c by 0.5% (p < .0001) at 6 months of the treatment. Liraglutide 3.0 mg treatment did not affect systolic blood pressure and alanine transferase. Liraglutide 3.0 mg resulted in clinically significant weight loss with better glycaemic control, confirming the drug's effectiveness in the real-world evidence setting.

show abstract

Section: Discussionsupporting

confidence: 92%

Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity‐related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real‐world experience

Alshehri,

AlFaris,

Al Qahtani

et al. 2023

Clinical Obesity

View full text Add to dashboard Cite

show abstract

“…The obesity and cardiovascular parameters were measured using standardized equipment by qualified research assistants according to international standards and references. The weight of the students was documented to the nearest 0.1 kg and height to the nearest 0.1 cm (Seca 704; Seca, Hamburg, Germany) [19]. Other measurements, such as waist circumference (WC) and hip circumference (HC), were obtained using a measuring tape to the nearest centimeter, as these are commonly used non-invasive biomarkers for predicting cardio-metabolic risk factors [20].…”

Section: Data Collection Toolsmentioning

confidence: 99%

The effect of moderate-intensity exercises on physical fitness, adiposity, and cardiovascular risk factors in Saudi males university students

El-Ashker

Al-Hariri

2023

JMedLife

Self Cite

View full text Add to dashboard Cite

Physical inactivity has been linked to several non-communicable diseases. This cross-sectional study investigated the impact of moderate-intensity exercise on physical fitness, adiposity, and cardiovascular risk factors in 284 Saudi male university students in the Eastern Province of Saudi Arabia between 2017 and 2019. The physical activity (PA) intervention comprised three (120 minutes each) sessions of moderate intensity on non-consecutive days each week, delivering a total of 360 minutes of PA per week for ten weeks. We measured physical fitness using VO 2 max calculations and assessed adiposity and cardiovascular risk factors using a range of parameters, such as systolic/diastolic blood pressure, heart rate, mean arterial pressure, body mass index, waist circumference, waist-to-height ratio, waist-to-hip ratio, body adiposity index, and body fat percentage. Our study found a significant increase in VO 2 max after ten weeks of moderate-intensity exercise (<0.001). Additionally, body adiposity indices were significantly reduced before and after the intervention (p<0.001), as were cardiovascular risk factors. Our findings suggest that regular moderate-intensity exercise effectively improves physical fitness, decreases adiposity, and lowers cardiovascular risk factors in Saudi male adults. We recommend that policymakers and public health practitioners increase physical activity among university students by launching a campaign on social media and through

show abstract

Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity

Valladales‐Restrepo

Sánchez-Ramírez

Usma-Valencia

et al. 2023

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients

Cited by 3 publications

References 35 publications

Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity‐related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real‐world experience

Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity‐related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real‐world experience

The effect of moderate-intensity exercises on physical fitness, adiposity, and cardiovascular risk factors in Saudi males university students

Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity

Contact Info

Product

Resources

About